Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Mild cognitive impairment Stories

2012-07-15 06:20:11

VANCOUVER, British Columbia, July 15, 2012 /PRNewswire-USNewswire/ -- Gait disturbances - such as a slowing of walking pace or a more variable stride - could indicate a decline in cognitive function, according to new research studies reported today at the Alzheimer's Association's International Conference® 2012 (AAIC® 2012). "With an aging baby boomer generation advancing into greater risk for Alzheimer's and dementia, it is important for physicians to be aware of the associations...

2012-07-11 06:25:59

LAS VEGAS and HAMILTON, N.J., July 11, 2012 /PRNewswire/ -- Cleveland Clinic Lou Ruvo Center for Brain Health and MedAvante, Inc. announced a collaborative alliance using MedAvante's centralized clinical trial services to optimize testing of treatments for Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and other neurodegenerative disorders. Dr. Jeffrey Cummings, Director of the Cleveland Clinic Lou Ruvo Center for Brain Health and one of the world's leading Alzheimer's disease...

2012-07-11 06:23:42

MIAMI, July 11, 2012 /PRNewswire/ -- ADEC Inc. - Worried about your memory? Many patients with Alzheimer's disease (AD) and individuals concerned about developing memory loss feel they have limited options. While there is no 'magic pill' to cure or prevent AD, a new book outlines a cutting-edge approach to systematically address this disease. Besides eating properly and exercising, there are several useful strategies for managing AD, according to Richard S. Isaacson,...

Memory In Patients With Early Alzheimer’s Improves From Nutrient Mixture
2012-07-10 15:20:27

In clinical trial, mixture developed at MIT appears to help overcome loss of connections between brain cells. A clinical trial of an Alzheimer´s disease treatment developed at MIT has found that the nutrient cocktail can improve memory in patients with early Alzheimer´s. The results confirm and expand the findings of an earlier trial of the nutritional supplement, which is designed to promote new connections between brain cells. Alzheimer´s patients gradually lose those...

2012-06-20 14:14:55

Innovative technique expected to play a critical role in diagnosis and treatment of disease The Mount Sinai Medical Center is the first institution in New York State to use in the clinical setting a newly approved imaging technique to detect Alzheimer's disease (AD) in people who are cognitively impaired. Until now, physicians have been limited in their ability to diagnose AD, guided almost exclusively by a patient's mental and behavioral symptoms and family history. The innovative...

2012-06-19 14:22:06

Ginger.io, of Cambridge, Mass, Recognized for Behavioral Analytics Platform Initiative Geoffrey Beene Gives Back® Alzheimer's Initiative to launch next round Innovation Competitions on Geoffrey Beene's Rock Stars of Science(TM) site WASHINGTON, June 19, 2012 /PRNewswire-USNewswire/ -- The Geoffrey Beene Gives Back® Alzheimer's Initiative (www.geoffreybeene.com/alzheimers.html) today announced Team Ginger.io, of Cambridge, Massachusetts, as the winner of the Alzheimer's Challenge...

2012-06-19 02:28:20

GRAND RAPIDS, Mich., June 19, 2012 /PRNewswire/ -- Tetra Discovery Partners LLC, a leader in the design of new treatments for major neurological conditions based on PDE4 modulation in the brain, today announced it has been awarded a five-year cooperative agreement by the National Institutes of Health (NIH). The award will support Tetra's efforts to develop a new drug to treat mild cognitive impairment, which is typically associated with aging and often precedes and accompanies Alzheimer's...

2012-06-14 02:25:22

VANCOUVER, June 14, 2012 /PRNewswire/ - Allon Therapeutics Inc. (TSX: NPC) said today that its shareholders have approved the terms of the $10 million brokered private placement equity offering previously announced by the Company May 2. The approval triggers the conversion of the subscription receipts sold as part of the financing making the full $10 million raised available to the Company for development of its lead product davunetide. Davunetide is proceeding in a fully enrolled...

2012-06-11 21:35:48

Studies show a naturally occurring protein called beta amyloid may be the key to diagnosis and could even be the answer to treating the neurodegenerative disease An arsenal of Alzheimer's research revealed at the Society of Nuclear Medicine's 59th Annual Meeting indicates that beta-amyloid plaque in the brain not only is involved in the pathology of Alzheimer's disease but may also precede even mild cognitive decline. These and other studies advance molecular imaging for the early...

2012-06-06 10:25:18

SUN CITY, Ariz., June 6, 2012 /PRNewswire/ -- A study by researchers at the Banner Sun Health Research Institute suggests that plasma levels of tau, a protein formed in the brain, appears to be a biomarker and a strong predictor for Alzheimer's disease. The study, led by Dr. Larry Speaks at the Banner Sun Health Research Institute (BSHRI), is published in the June edition of American Journal of Neurodegenerative Disease. Sparks and other researchers measured tau levels in human plasma and...